Aurora Cannabis Inc (TSE: ACB) (NASDAQ: ACB) observed a significant share surge on Wednesday after reporting record dollar figures in its fiscal 2025 Q3 results. The stock rose by over 47 per cent on the TSX to C$7.81.
The Canadian cultivator primarily attributes these successes to international medical cannabis sales.
Aurora reported an all-time high net revenue of C$68.1 million for its global medical marijuana business during the quarter, marking a 51 per cent year-over-year (YoY) increase. This achievement coincides with the company’s establishment of its first German medical brand late last month — IndiMed. Aurora is one of only three certified cultivators in the country.
The multinational supplier also reported record earnings before interest, taxes, depreciation and amortization (EBITDA) of C$23.1 million during the three-month period ending Dec. 31, representing a massive 316 per cent increase in comparison to the previous year.
Total net revenue clocked in at C$88.2 million — a 37 per cent YoY ascent. Moreover, Aurora’s net income rose by 282 per cent year-over-year to C$31.2 million.
“These achievements, along with our strong cash position and debt-free cannabis business, underscore Aurora’s leadership in the global cannabis industry,” chief executive Miguel Martin boasted. Aurora currently has a cash balance of C$180 million.
In addition to Canada and Germany, nations where Aurora distributes medical cannabinoid products include New Zealand, Israel, Australia, Brazil and Uruguay. It has established multiple brands — such as Aurora Europe, MedRelief Australia and ICC labs — that cater to these markets.
Cultivated Live with Miguel Martin, CEO, Aurora Cannabis https://t.co/6KXsoIdDoS
— Jeremy Berke (@jfberke) February 5, 2025
Read more: Cannabis consumption among pregnant Ontario women increased 2.5-fold in 10 years
Read more: Aurora establishes 1st German medical brand as nation’s industry takes flight
Aurora shows German students the cultivation ropes
Aside from a substantial stock bump linked to a high-performance quarter and the establishment of a German medical brand, Aurora has had some other recent notable activity in Europe.
Last month, the grower started offering six-month internships to students from Germany’s Erfurt University of Applied Sciences at its cultivation facility in the European nation’s town of Leuna.
“The six-month internship program will focus on all phases of medical cannabis cultivation,” Aurora specified in a news release on Jan. 10, “including cloning, care, harvesting, packaging and cleaning.”
A couple weeks earlier, the cultivator announced a new distribution agreement in Australia with The Entourage Effect — an Aussie medical cannabis distributor catering to pharmacies nationwide. Aurora will supply the company with products from its MedRelief Australia brand.
These recent developments highlight the company’s extensive reach in the global cannabis sector and its growing footprint. The industries in Germany and Australia in particular are expected to have robust growth in the coming years.
rowan@mugglehead.com
